Braskem (OTCMKTS:BRKMY – Get Rating) and Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) are both oils/energy companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Profitability
This table compares Braskem and Cyclo Therapeutics' net margins, return on equity and return on assets.
Get Braskem alerts:| Net Margins | Return on Equity | Return on Assets | |
| Braskem | 3.18% | 26.96% | 3.00% |
| Cyclo Therapeutics | -747.63% | -120.38% | -95.12% |
Earnings & Valuation
This table compares Braskem and Cyclo Therapeutics' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Braskem | $18.79 billion | 0.19 | $773.65 million | $1.23 | 7.30 |
| Cyclo Therapeutics | $1.59 million | 9.92 | -$14.29 million | ($1.58) | -1.18 |
Institutional and Insider Ownership
0.1% of Braskem shares are held by institutional investors. Comparatively, 4.7% of Cyclo Therapeutics shares are held by institutional investors. 0.0% of Braskem shares are held by insiders. Comparatively, 12.0% of Cyclo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Braskem and Cyclo Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Braskem | 0 | 0 | 0 | 0 | N/A |
| Cyclo Therapeutics | 0 | 0 | 0 | 0 | N/A |
Risk & Volatility
Braskem has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500.
Summary
Braskem beats Cyclo Therapeutics on 8 of the 11 factors compared between the two stocks.
About Braskem
(Get Rating)
Braskem S.A., together with its subsidiaries, produces and sells thermoplastic resins. The company operates through Chemicals, Polyolefins, Vinyls, United States and Europe, and Mexico segments. The Chemicals segment produces and sells ethylene, propylene butadiene, toluene, xylene, cumene, and benzene, as well as gasoline, diesel and liquefied petroleum gas, and other petroleum derivatives; and supplies electric energy, steam, compressed air, and other inputs to second-generation producers. The Polyolefins segment produces and sells polyethylene and polypropylene. The Vinyls segment produces and sells polyvinyl chloride, caustic soda, and chloride. The United States and Europe segment produces and sells polypropylene in the United States and Europe. The Mexico segment produces and sells polyethylene. The company also produces basic petrochemicals; imports and exports chemicals, petrochemicals, and fuels; produces, supplies, and sells utilities, such as steam, water, compressed air, and industrial gases; and provides industrial services. The company was formerly known as Copene Petroquímica do Nordeste S.A. and changed its name to Braskem S.A. in 2002. Braskem S.A. was founded in 1972 and is headquartered in São Paulo, Brazil. Braskem S.A. is a subsidiary of Odebrecht S.A.
About Cyclo Therapeutics
(Get Rating)
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Receive News & Ratings for Braskem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braskem and related companies with MarketBeat.com's FREE daily email newsletter.